An antagonist of ATP-regulated potassium channels, the guanidine derivative U-37883A, stimulates the synthesis of phosphatidylserine in rat liver endoplasmic reticulum membranes  by Makowski, Piotr et al.
FEBS Letters 409 (1997) 292-296 FEBS 18672 
An antagonist of ATP-regulated potassium channels, the guanidine 
derivative U-37883A, stimulates the synthesis of phosphatidylserine in rat 
liver endoplasmic reticulum membranes 
Piotr Makowskia, Adam Szewczykb, Renata Jasinskaa, Slawomir Pikulaa* 
*Department of Cellular Biochemistry, Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland 
bDepartment of Muscle Biochemistry, Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland 
Received 14 March 1997 
Abstract The guanidine derivative U-37883A has been found to 
stimulate in vitro synthesis of phosphatidylserine in endoplasmic 
reticulum membranes, catalyzed exclusively by a serine-specific 
base exchange enzyme. The stimulation of the enzyme activity by 
the drug was concentration-dependent, with EC50 of 54 μΜ, 
while the biologically inactive analog of U-37883A, U-42069, 
was without effect. The stimulation caused by U-37883A was 
enhanced under the conditions when active transport of Ca2+ into 
the lumen of microsomal vesicles was induced, whereas it was 
inhibited by a calcium ionophore, A23187, and by a specific 
inhibitor of Ca2+-ATPase, thapsigargin. On the other hand, a 
potassium ionophore, valinomycin, had no effect on phosphati-
dylserine synthesis. U-37883A did not affect the Km of the base 
exchange enzyme for serine, but greatly reduced the EC50 value 
of the enzyme for calcium. Furthermore, Ca2+ uptake by 
endoplasmic reticulum vesicles has been found to increase in 
the presence of U-37883A. These observations suggest that 
U-37883A enhances phosphatidylserine synthesis indirectly by 
acting on calcium transport, thus affecting calcium concentration 
within the lumen of endoplasmic reticulum membranes. Alter-
natively, the effect of the drug could be propagated via the 
mechanism by which phospholipid flip-flop movement, known to 
regulate the serine-specific base exchange reaction, is modulated. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The amount of phosphatidylserine (PS) in mammalian cell 
membranes varies from 1 to 10 mol% of total phospholipids, 
and is usually tissue specific [1]. PS is asymmetrically distrib-
uted within the transversal plane of biological membranes, on 
the cytoplasmic leaflet of plasma membranes and on the ex-
tracytoplasmic side of intracellular ones, for example of endo-
plasmic reticulum (ER) membranes [2-Λ]. Such a localization 
of this phospholipid can be transiently modulated upon met-
abolic activation of a cell [4] or in various pathologies. PS is 
solely formed by a unique enzyme catalyzed, bi-substrate 
phospholipid base exchange (PLBE) reaction [5] in ER mem-
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branes of mammalian cells. It has been documented [6] that, 
in rat liver ER membranes, the specific stearoyl-polyunsatu-
rated molecular species of phosphatidylethanolamine (PE) 
and phosphatidylcholine (PC) are preferentially converted to 
PS via this reaction. Since, the PLBE reaction is calcium-de-
pendent, the activities of various ER membranes proteins in-
fluencing calcium homeostasis within a cell, like Ca2+-ATPase 
[7] or electron transport systems, cytochrome P450 isoforms 
and other metalloproteins [8], are potential modulators of the 
efficiency of PS synthesis. On the other hand, PE formed from 
the proper molecular species of PS by the ethanolamine-spe-
cific PLBE reaction [9], and PS itself, are both main bulk 
phospholipids which create the membrane environment for 
the activity of cytochrome P450 isoforms [10]. Recently, a 
close relationship between PS synthesis, cytochrome P450 
and K+ channel activities has been postulated [11,12], since 
imidazole antimycotics, inhibitors of cytochrome P450 iso-
forms, i.e. clotrimazole, econazole, miconazole and oc-naphto-
flavone [11] at submicromolar or micromolar concentrations, 
as well as K+ channel blockers and antiarrhythmic drug, i.e. 
quinine, quinidine, 4-aminopyridine, tetraethylammonium and 
clofilium [11-13], were found to enhance the efficiency of PS 
synthesis in Jurkat T lymphocytes, independently on Ca2+-
influx and plasma membrane potential [11]. On the other 
hand, the inhibition of PC and PE synthesis in these cells 
by antiarrhythmic drugs has been observed [13]. 
The ATP-regulated potassium (KATP) channels, well char-
acterized in plasma membranes of various cells [14], were also 
identified, by the use of KATP channel antagonists: antidia-
betic sulfonylureas and non-sulfonylureas, or various potassi-
um channel openers, in rat liver mitochondria [15]. It was, 
therefore, of particular interest to examine the effects of 
KATP channel antagonists on PS synthesis in rat liver ER 
membranes, the main site of phospholipid synthesis in a cell. 
2. Materials and methods 
2.1. Chemicals 
KATP channel inhibitors were obtained from the following sources: 
4 - morpholine - carboxamidine - JV-1 - adamantyl - N' - cyclohexylhydro-
chloride (U-37883A), [3H]U-37883A (32.8 Ci/mmol), and 4-morpho-
linecarboxamidine (U-42069D) were a generous gift from Unpjohn 
Co. (USA), glibenclamide was obtained from Research Biochemicals 
Inc. (USA), and glipizide, HB985 and HB699, were kindly supplied by 
Hoechst (Germany). [3-14C]Serine (51 mCi/mmol) was purchased 
from Amersham (UK). HEPES, ATP, A23187, and valinomycin 
were from Sigma (USA). All other chemicals were of the highest 
purity commercially available. 
2.2. Microsomes 
Adult male Wistar rats weighing 150-180 g were killed after being 
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starved for 16 h. Liver ER membranes were prepared according to 
Rakowska et al. [16], resuspended at a protein concentration of 10-20 
mg/ml in a buffer containing 250 mM sucrose, 40 mM HEPES, pH 
7.4, and stored at -72°C. 
2.3. Measurements of phospholipid base exchange activity 
The reaction mixture for measurements of PLBE activity contained 
0.25 mg of microsomal protein (equivalent to 130 ±12 nmoles of 
phospholipids) in 0.25 ml of 40 mM K-HEPES, pH 7.4, supplemented 
with 50 μΜ CaCl2, 50 μΜ [3-
14C]serine (1.5 mCi/mmol), and when 
indicated with 1 mM MgCi2+1.2 mM ATP. In some experiments, the 
concentrations of serine and CaCl2 varied, and the reaction mixture 
was supplemented with various concentrations of a KATP antagonist. 
The reaction was carried out at 37°C in a water bath shaker for 15-20 
min, the period when the PLBE activity remained linear. The PLBE 
reaction was stopped by addition of 2.0 ml of ice-cold chloro-
form : methanol mixture (1:1, v/v), followed by addition after 
15 min of 1 ml of 0.1 N HC1. The organic phase was separated by 
centrifugation, washed twice with 1.0 ml of 1 mM serine in methanol, 
and evaporated to dryness. The incorporation of radiolabelled sub-
strate into PS was assessed by scintillation counting in a Beckman LS 
6000TA counter (USA). In each assay non-incubated blank samples 
(immediately after addition of substrate) were used to measure non-
specific binding of serine to ER membranes (which did not exceed 1% 
of total lipid-associated radioactivity), which was subsequently sub-
tracted from the respective experimental data. 
2.4. Uptake of calcium by rat liver ER membranes 
The uptake of Ca2+ by microsomal vesicles (0.7 mg of protein 
ml - 1) was measured in a medium containing 20 mM K-HEPES, pH 
7.0, 100 mM KC1, 2 mM MgCl2, 80 μΜ
 45CaCl2 (30 mCi/mmol), and 
various concentrations of K-EGTA, to obtain the final [Ca2+] as in-
dicated in the abscissa to Fig. 3A or the fixed concentration of cal-
cium estimated to be 3.7 μΜ when 0.1 mM K-EGTA was present 
(Fig. 3B). Vesicles were preincubated for 5 min at 37°C, then K-ATP, 
pH 6.8, was added to reach a final concentration of 1 mM, and 
incubation was carried out at the same temperature for 1 to 5 min. 
At various time points, 500-μ1 aliquots were withdrawn and filtered 
through Millipore filters (0.45 μιη, type HAWP, Millipore Corp.) 
prewashed with 2 x 2 ml of 20 mM K-HEPES, pH 7.4, 100 mM 
KC1. The filters were immediately washed twice with 2 ml of the 
same ice-cold medium. Filter-associated radioactivity was counted in 
dioxane scintillator. 
2.5. Binding of [ΆΗ]υ-37883Α to endoplasmic reticulum membranes 
Binding of radiolabelled U-37883A to ER membranes was assayed 
as follows. For the equilibrium binding assay, rat liver ER membranes 
(300-500 μg protein ml - 1) were incubated for 60 min at 4°C in 
50 mM HEPES-NaOH (pH 7.4), with the required concentrations 
of [3H]U-37883A (2 nM-20 μΜ, 32.8 Ci/mmol). The incubation was 
stopped by rapid filtration through Whatman GF/C filters under re-
duced pressure. Prior to use, the filters were immersed and incubated 
in a solution containing 0.5% polyethyleneimine-HEPES, pH 7.4, fol-
lowed by washing in 30 ml of 100 mM NaCl, 20 mM Tris-HCl, pH 
7.4, at 4°C. Subsequently, the filters were incubated for 24 h in 5 ml of 
Formula 989 (DuPont NEN, Germany) as a scintillation cocktail, and 
counted for associated radioactivity. Non-specific binding was meas-
ured in the presence of 30 μΜ non-radioactive U-37883A. 
2.6. Other procedures 
Protein concentration was determined according to Bradford [17] 
with bovine serum albumin as a standard. Phospholipids were ex-
tracted from membranes according to Bligh and Dyer [18], and quan-
tified by inorganic phosphorus measurements, as described by Rouser 
et al. [19]. Free calcium concentrations were calculated with the aid of 
a computer program and the log ÄaEGTA values of Vianna [20], and 
verified using a Ca2+-selective electrode (Orion, Res. Inc., USA). 
3. Results and discussion 
3.1. Influence of U-37883A on phosphatidylserine synthesis via 
the phospholipid base exchange reaction 
The transport activity of K A T P channels of plasma mem-
Fig. 1. The effect of non-sulfonylurea KATP channel inhibitor, guanidine derivative U37883A, on synthesis of phosphatidylserine in rat liver en-
doplasmic reticulum membranes. (A) The PLBE reaction was performed at protein concentration of 1 mg ml - 1 , in 40 mM K-HEPES, pH 7.4, 
50 μΜ [3-14C]serine, 50 μΜ CaCl2, with no further additions, or with 1 mM MgCl2, 1.2 mM ATP, and ± 100 μΜ U-37883A, for 15 min at 
37°C. (B) The concentration dependence of the effect of U-37883A ( · ) or U-42069D (o) on the serine-specific base exchange reaction in the 
presence of 1 mM MgCi2, 1.2 mM ATP and 50 μΜ CaCb. The determinations of PLBE activity were performed as described in Section 2. 
The drugs were used at the concentrations indicated on the abscissa. ER membranes were not preincubated with these drugs before the assay 
of enzyme activity. Mean values ± SD of three experiments are shown. Inset to panel B: chemical formula of U-37883A. 
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Fig. 2. The influence of 100 μΜ U-37883A on kmetic parameters of the serine-specific base exchange reaction. (A) The effect of the guanidme 
derivative U-37883A (·) on Km of the reaction with serine as a substrate. The control experiment was performed in the absence of guanidine 
derivative (o)· (B) Calcium dependence of PS synthesis in the absence (o) or presence (·) of U-37883A. Other conditions are described in Sec-
tion 2. ER membranes were not preincubated with U-37883A prior to the assay of PLBE activity. In the inset to B, the double reciprocal plot 
is shown. The data are combined from four independent experiments. 
branes is inhibited by sulfonylureas [21], which serve as potent 
medicaments in the therapy of diabetes mellitus type II, and 
by non-sulfonylureas like U-37883A [22]. The KATP channels 
are activated by potassium channel openers, which are fre-
quently used in medical treatment of hypertension [23]. Addi-
tionally, it has been shown that sulfonylureas are able to enter 
the cytosol and bind to intracellular membranes, insulin con-
taining granules [24] and liver mitochondria [15]. It has been 
also found that a non-sulfonylurea blocker of KATP channels, 
U-37883A (inset to Fig. IB), regulating in vivo the function of 
kidney, i.e. natriuresis/diuresis [25], inhibits K+ uniport in rat 
liver mitochondria [26]. 
We have tested the effect of antidiabetic sulfonylureas and 
U-37883A on PS synthesis in ER membranes in vitro. All the 
antidiabetic sulfonylureas applied, glibenclamide, glipizide, 
HB985, and HB699, even at 100 μΜ concentration, were un-
able to affect significantly PS synthesis at 1 mM CaCl2 con-
centration, equal to EC50 value of the PLBE reaction [16]. In 
contrast, stimulation of PS synthesis by 100 μΜ U-37883A 
was observed at 1 mM CaCl2, as well as at 50 μΜ CaCl2 (Fig. 
1A), suggesting a direct interaction of this drug with micro-
somal membranes. In fact, single class of low-affinity binding 
sites with K¿ of 9 μΜ was identified in microsomal mem-
branes using [3H]U-37883A. To check whether the U-37883A-
stimulated PS synthesis was due to the influence of this drug 
on K+ permeability of SR/ER membranes [27] the efficiency 
of PS synthesis was measured in the presence of valinomycin, 
a K+ ionophore. No effect of valinomycin was observed on 
U-37883A-stimulated PS synthesis, indicating that neither the 
ER membranes K+ channel nor changes in membrane poten-
tial [16] are involved in the observed phenomena. On the other 
hand, a K+ channel modulator, glibenclamide, has been im-
plicated to affect calcium homeostasis in various cells and 
tissues [28]. Therefore, it seemed of particular interest to check 
the influence of sulfonylureas (glibenclamide, glipizide, 
HB985, and HB699) and U-37883A on PS synthesis in ER 
membranes under the conditions when Ca2+-transport ATP-
ase was activated. We found that only 100 μΜ U-37883A 
enhanced PS synthesis via the PLBE reaction when the assay 
medium was supplemented with 1.2 mM Mg-ATP, and the 
Ca2+ concentration was 19 μΜ [20]. Stimulation of PS syn-
thesis by the K+ channel antagonist at 1.2 mM Mg-ATP and 
19 μΜ Ca2+ was found to be drug-concentration dependent 
with EC50 value of 54 μΜ (Fig. IB). Under the same condi-
tions the analog of U-37883A, designated U-42069, which was 
found biologically inactive [25,26], did not affect PS synthesis 
in rat liver ER membranes, although it was used over a broad 
concentrations range (Fig. IB). The stimulation of PS syn-
thesis by U-37883A was synergistic with the effect of Mg-
ATP at 50 μΜ CaCl2. The efficiency of PS synthesis in the 
presence of U-37883A exhibited a linear dependence versus 
reaction time, up to 15-20 min at 37°C, and was almost by 
a factor of two enhanced in comparison to control ER mem-
branes (with no drug added) (Fig. 1A). At the same time 
1.7-fold stimulation of the PLBE reaction in the presence of 
1.2 mM Mg-ATP was observed. Both effectors added together 
increased the efficiency of PS synthesis by a factor of 3 at 
50 μΜ CaCl2. Preincubation of ER membranes with 
U-37883A for 15 s to 20 min at 4°C had no significant in-
fluence on the reaction (not shown), suggesting indirect effect 
of the drug on serine-specific PLBE enzyme. 
3.2. Kmetic parameters of serine-specific phospholipid base 
exchange reaction upon addition of U-37883A 
To study the mechanism by which the applied guanidine 
derivative may activate in vitro PS synthesis in ER mem-
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Fig. 3. The effect of U-37883A on calcium uptake by ER membranes. (A) The concentration dependence of 45Ca2+ uptake by ER membranes 
not treated with the guanidine derivative was assayed under the conditions specified in Section 2. (B) The time-course of calcium (final [Ca2+] 
3.7 μΜ) uptake by ER membranes in the absence (o) or presence (·) of 100 μΜ U-37883A. Mean values ±SD for three different membrane 
preparations are shown. 
branes we have examined kinetic parameters of the PLBE 
reaction. As shown on Fig. 2A, hyperbolic regression curves 
for serine concentration versus reaction velocity measured in 
the absence or presence of 100 μΜ U-37883A, suggest that the 
serine-specific PLBE obeys in both cases first order kinetics 
characterized by the Michaelis-Menten law. The Km value for 
serine in the presence of 50 μΜ CaCb and 1.2 mM Mg-ATP 
calculated on the basis of the data obtained for control sam-
ples, was found to be 31 ±8 μΜ, i.e. similar to that reported 
by other authors [29,30], and Vmax of 16 ± 3 pmol per mg 
protein per min. In comparison, in the presence of 
U-37883A, Km of the PLBE reaction for serine was not af-
fected (22 ± 3 μΜ), while Kmax value increased more than 
three-fold (Fig. 2A). This prompted us to conclude once again 
that the effect of U-37883A on the PLBE enzyme is rather 
indirect, because it neither does change the affinity of the 
enzyme for serine nor the permeability of ER membranes to 
aminoalcohol (not shown). Moreover, the membrane is not 
destroyed by U-37883A, as phospholipid synthesis via the 
PLBE reaction was found to be dependent on membrane in-
tegrity [16]. Since the Vmax value of the reaction was signifi-
cantly enhanced by the drug, it can be speculated that this was 
due to changes in phospholipid movement across the mem-
brane bilayer or in calcium transport-related events. Since 
amphiphilic cations and anions have no effect on the Km value 
towards L-serine but only upon the Kmax value of the reaction, 
it was suggested that their effect was related to interaction of 
the lipid substrate with the PLBE enzyme [31]. 
As we reported previously, the EC5o value for the serine-
specific PLBE reaction with respect to Ca2+ concentrations is 
in the range of 0.6-0.8 mM [16]. In the presence of Mg-ATP, 
the EC50 value of the reaction for calcium was lowered by 
U-37883A from 810 μΜ in control ER membranes to 150 μΜ 
(Fig. 2B), as confirmed by the double reciprocal plot shown 
on inset to the figure. This result can be explained by the effect 
of the drug on permeability of ER membranes to Ca2+. 
3.3. The effect of U-37883A on Ca2+ requirement of 
serine-specific phospholipid base exchange reaction 
PS synthesis in rat ER membranes is inhibited in vitro by 
calcium antagonists, A23187, caffeine, thapsigargin, and va-
nadate [32,33], as it was also observed in vivo in Jurkat T cells 
[13] and glioma C% cells [34]. On the other hand, PS synthesis 
in rabbit platelets [35], human leukocytes [36], and Jurkat T 
cells [37] was activated by calmodulin antagonists, chlorpro-
mazine, trifluoroperazine, and N-(6-aminohexyl)-5-chloro-l-
naphthalene-sulphonamide hydrochloride. These cationic am-
phiphilic drugs acted synergistically to Ca2+ since their effect 
was reversed by the addition of EGTA [37]. Millimolar con-
centrations of calcium required for maximal activation of the 
PLBE reaction are reached in a cell only within the lumen of 
ER membranes [7]. Therefore this reaction either occurs inside 
microsomes [32,33] or a calcium-responsive domain of the 
PLBE enzyme is localized on the luminal side of ER mem-
branes [16], where the concentration of this cation is limited in 
vivo by the presence of Ca2+-binding proteins, such as calm-
odulin [8], calnexin [38] and calreticulin [39], as well as by 
negatively charged phospholipids [40]. In hepatocytes, the 
ER-dependent cellular calcium homeostasis is also regulated 
by cytochromes P450 [8], by the level of phosphate released 
from glucose-6-phosphate [41], by the inositol 1,4,5-trisphos-
phate-dependent pathway, and by Ca2+-mobilizing hormones, 
vasopressin, glucagon and insulin [42]. 
Since, depletion of calcium stores inhibits PS synthesis 
[13,33], 45Ca2+ uptake measurements were performed in the 
presence of U-37883A (Fig. 3B) and under the conditions 
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described as optimal for Ca2+-ATPase activity [43]. The rate 
of calcium ion accumulation versus Ca2+out. concentration 
fitted well the sigmoidal-shaped curve (Fig. 3A) and allowed 
us to estimate maximal Ca2+ accumulation to be 1 nmol per 
mg protein per 3 min at 37°C. This value is in agreement with 
those previously reported by other investigators [44]. The up-
take was sensitive to calcium ionophores (A23187) and Ca2+-
ATPase inhibitors (thapsigargin), as it was also shown by 
others [33]. U-37883A (100 μΜ) stimulated calcium uptake 
by 30% (Fig. 3B), resulting in an increase of Ca2+ concentra-
tion inside ER membranes by one order of magnitude (taking 
into account that internal volume of ER vesicles is 2-2.5 μΐ 
per mg protein [16]). In addition, the stimulatory effect of 
U-37883A on PS synthesis was completely reversed in the 
presence of 250 nM thapsigargin or by 1 μΜ Α23187. There-
fore, the influence of the drug studied on calcium transport 
and/or other calcium-related processes (like redistribution of 
phospholipids, flip-flop) rather than directly on the protein 
catalyzing PLBE reaction should be considered as responsible 
for stimulation of PS synthesis. Changes of PS amount in 
intracellular membranes may have profound effects in vivo. 
PS, due to its net negative charge at physiological pH, inter-
acts with amino group of proteins, and with inorganic cations. 
Calcium interaction with PS headgroup has been found to 
evoke changes in its configuration, in the molecular area oc-
cupied by the phospholipid, and the surface charge density 
[45], these changes leading to lateral phase separation, to for-
mation of local lipid domains in membranes [40], and affect-
ing localization of PS in the transversal plane of bilayer [2-
4,46,47]. Moreover, there are numerous intracellular proteins, 
among them protein kinase C isoforms, phospholipase A2 or 
annexins, which have been found to specifically bind PS in 
membrane bilayers in the presence of calcium ions, forming 
ternary calcium/lipid/protein complexes, essential for their bi-
ological activity [48]. 
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